

## TURKEY

### Recent and planned developments in pharmaceutical policies 2016

#### Special topic: Out-of pocket payments

D E V E L O P M E N T S	<b>CHANGES IN PRICING</b>	<b>CHANGES IN REIMBURSEMENT</b>
	<ul style="list-style-type: none"> <li>• <i>No changes</i></li> </ul>	<ul style="list-style-type: none"> <li>• <i>Alternative reimbursement models (mostly financial based price-volume agreements) for high priced or unlicensed medicines since February 2016.</i></li> <li>• <i>06/2016: Reimbursement of novel hepatitis C medicines (Sovaldi, Harvoni, Exviera and Viekirax by risk-sharing agreement.</i></li> <li>• <i>06/2016: Delisting of telaprevir and boseprevir because of novel hepatitis C medicines</i></li> </ul>
	<b>OTHER CHANGES</b>	
S P E C I A L  T O P I C	<b>OUT-OF POCKET PAYMENTS</b>	
	<ul style="list-style-type: none"> <li>• <i>%20 copayment for insured people and dependents also %10 for retired people and their dependents per prescription.</i></li> <li>• <i>A fixed fee for prescriptions from second and third line healthcare facilities.</i></li> <li>• <i>Copayment for medicines which its price is higher than %10 of its base line price of generic cluster.</i></li> <li>• <i>Exemption from copayments for chronic diseases such as cancer, hypertension, diabetes etc. Apart from that there isn't any specific policy for any vulnerable group.</i></li> </ul> <p><i>Patients don't need to pay for medicines when they stay in in-patient settings.</i></p>	